Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
15
XFOR Quote, Financials, Valuation and Earnings
Last price:
$3.41
Seasonality move
:
-5.35%
Day range:
$3.38 - $3.51
52-week range:
$1.35 - $16.29
Dividend yield:
0%
P/E ratio:
0.70x
P/S ratio:
1.61x
P/B ratio:
4.84x
Volume:
160.8K
Avg. volume:
400.1K
1-year change:
-77.38%
Market cap:
$298.2M
Revenue:
$2.6M
EPS (TTM):
-$10.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$1.7M | -$0.36 | -82.99% | -93.89% | $9.33 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.6% | -58.59% | $459.40 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.67 | 11.8% | 33.07% | $88.65 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$3.41 | $9.33 | $298.2M | 0.70x | $0.00 | 0% | 1.61x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.03 | $31.21 | $3.7B | 14.17x | $0.00 | 0% | 3.54x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$314.40 | $459.40 | $41.7B | 139.29x | $0.00 | 0% | 11.30x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.87 | $88.65 | $11.5B | 22.43x | $0.00 | 0% | 3.79x |
|
IMNN
Imunon, Inc.
|
$3.25 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.60 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
55.66% | 2.502 | 89.95% | 5.25x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XFOR
X4 Pharmaceuticals, Inc.
|
$1.4M | -$27.5M | -84.9% | -279.19% | -1558.58% | -$27.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
X4 Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns XFOR or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of 25.76%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About XFOR or ACAD?
X4 Pharmaceuticals, Inc. has a consensus price target of $9.33, signalling upside risk potential of 173.71%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 41.67%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is XFOR or ACAD More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.461, which suggesting that the stock is 53.939% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock XFOR or ACAD?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or ACAD?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.61x versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.61x 0.70x $1.8M -$29.8M ACADACADIA Pharmaceuticals, Inc.3.54x 14.17x $278.6M $71.8M
-
Which has Higher Returns XFOR or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of 16.99%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About XFOR or ALNY?
X4 Pharmaceuticals, Inc. has a consensus price target of $9.33, signalling upside risk potential of 173.71%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $459.40 which suggests that it could grow by 48.74%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is XFOR or ALNY More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.461, which suggesting that the stock is 53.939% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock XFOR or ALNY?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or ALNY?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.61x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.61x 0.70x $1.8M -$29.8M ALNYAlnylam Pharmaceuticals, Inc.11.30x 139.29x $1.1B $186.4M
-
Which has Higher Returns XFOR or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -3.91%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About XFOR or BMRN?
X4 Pharmaceuticals, Inc. has a consensus price target of $9.33, signalling upside risk potential of 173.71%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.65 which suggests that it could grow by 48.07%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is XFOR or BMRN More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.461, which suggesting that the stock is 53.939% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock XFOR or BMRN?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or BMRN?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.61x versus 3.79x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.61x 0.70x $1.8M -$29.8M BMRNBioMarin Pharmaceutical, Inc.3.79x 22.43x $786.8M -$30.7M
-
Which has Higher Returns XFOR or IMNN?
Imunon, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of --. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About XFOR or IMNN?
X4 Pharmaceuticals, Inc. has a consensus price target of $9.33, signalling upside risk potential of 173.71%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 561.54%. Given that Imunon, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Imunon, Inc. is more attractive than X4 Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 IMNNImunon, Inc.3 1 0 -
Is XFOR or IMNN More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.461, which suggesting that the stock is 53.939% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock XFOR or IMNN?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or IMNN?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Imunon, Inc. quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.61x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.61x 0.70x $1.8M -$29.8M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns XFOR or SVRA?
Savara, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of --. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital XFORX4 Pharmaceuticals, Inc.78.81% -$0.69 $139M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About XFOR or SVRA?
X4 Pharmaceuticals, Inc. has a consensus price target of $9.33, signalling upside risk potential of 173.71%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.08%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XFORX4 Pharmaceuticals, Inc.3 0 0 SVRASavara, Inc.6 0 0 -
Is XFOR or SVRA More Risky?
X4 Pharmaceuticals, Inc. has a beta of 0.461, which suggesting that the stock is 53.939% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock XFOR or SVRA?
X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XFOR or SVRA?
X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Savara, Inc. quarterly revenues of --. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Savara, Inc.'s net income of -$29.6M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 1.61x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XFORX4 Pharmaceuticals, Inc.1.61x 0.70x $1.8M -$29.8M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
